Download Free Innovative Concepts In Inflammatory Bowel Disease Book in PDF and EPUB Free Download. You can read online Innovative Concepts In Inflammatory Bowel Disease and write the review.

Chronic inflammatory bowel diseases represent an important medical problem, since they have a devastating impact on the quality of life and require longstanding medical care. Many medical disciplines are involved in tackling the immensely complex studies on pathogenesis, clinical expression and treatment possibilities. This book, the proceedings of the Falk Symposium 105 on `Innovative Concepts in Inflammatory Bowel Diseases', held in Rostock, Germany, on April 30 - May 2, 1998, brought together experts from different fields of science to allow a unified view on clinical and basic research. The main themes of the meeting were genetics, animal models, immunology, epithelial cells, endotoxin, diagnostic procedures, malignancy, medical therapies, and surgery. In each section of the book experts present state-of-the-art reviews with the very latest developments in the respective research areas followed by chapters on different aspects of inflammatory bowel diseases. They provide suggestions concerning future research and clinical management of patients with inflammatory bowel diseases.
Few human illnesses today are so challenging, medically, scientifically, and socio-economically, as the "nonspecific" inflammatory bowel diseases (IBD): ulcerative colitis and Crohn's disease. Originating several centuries ago but essentially diseases of the 20th century, often attacking children and young adults, involving all bodily systems as well as the gastrointestinal tract, ulcerative colitis and Crohn's disease have emerged in recent decades as among the more "glamorous" unsolved diseases, presenting unusual opportunities for insightful clinical and investigative study. Many of the prevailing concepts originated during the early and mid 20th century. The purpose of Origins and Directions of Inflammatory Bowel Disease is to review these earlier studies and their evolution "from the mystical to the molecular," and guide investigators and physicians through the challenging clinical and scientific maze of IBD.
This is the state-of–the-art book on inflammatory bowel disease you have been waiting for Written and edited by international experts in gastroenterology this up-to-date volume provides a complete review of the basic science behind inflammatory bowel disease (IBD), as well as evidence-based clinical guidance on diagnosis, treatment and long-term management of IBD. In 50 chapters the authors cover the latest and most promising treatment modalities and the science behind them. There are chapters which cover the advances in the medical and surgical treatment of conditions such as Crohn's disease and ulcerative colitis, as well as chapters focusing on nutrition, imaging and complementary medicine. This is an invaluable information resource for all those in the medical team treating patients with IBD. Whether you are a gastroenterologist, gastrointestinal surgeon or GI nurse specialist this book deserves a place in your library.
This book is the proceedings of the Falk Symposium No. 122 on "Inflammatory Bowel Disease - A Clinical Case Approach to Pathophysiology, Diagnosis, and Treatment", held in Bologna, Italy, on June 22-23, 2001, and deals with some major issues concerning Genetics of IBD, Pediatrics in IBD, Early vs Late IBD, Bacteria and Gut Inflammation, Refractory CD, Fistulizing CD, Refractory Distal Colitis, and Complications of Ileal-Pouch Anastomosis. The main aim of the meeting was to highlight the value of an integrated clinical approach and the importance of clinical research in developing innovative methods of treatment.
This book, the proceedings of Falk Symposium 130 on 'Gastrointestinal Inflammation and Disturbed Gut Function: The Challenge of New Concepts', held in Freiburg, Germany, on October 4-6, 2002 (Part I of the Gastroenterology Week Freiburg 2002), reviews ground-breaking work and will stimulate new research in the functional GI disorders, from the bench to the bedside. Basic scientists, clinical researchers and clinicians interested in this field explore controversial and exciting areas of research, and consider targets for future therapeutic interventions.
The aetiology of the chronic inflammatory bowel diseases - Crohn's disease and ulcerative colitis - is still enigmatic. The therapeutic approach has therefore traditionally focused on anti-inflammatory principles, including corticosteroids and aminosalicylates. Since a significant proportion of patients is steroid-dependent or refractory and because of the problematic side-effects of long-term systemic steroids, active immunosuppression has gained acceptance in the field. The classical immunosuppressants azathioprine and 6-mercaptopurine have long been evidence-based in IBD, but underused. Recently, methotrexate and cyclosporine have also been proven to be effective in certain situations. Newer drugs like tacrolimus, mycophenolate and others may be similarly useful but their potential is still unclear. Finally, the immune modifiers including IL-10 and TNF-antibodies have been successfully subjected to controlled trials. Other experimental drugs discussed in this book are on the horizon. This volume is the Proceedings of Falk Symposium 119 held in Freiburg-im-Breisgau, Germany, October 3-4, 2000, and covers systematically the field of immunosuppression in inflammatory bowel diseases. It is hoped that it will further the prudent use of these drugs in the proper clinical situations by increasing our understanding of both the mechanisms of action and the clinical benefit to the patient.
This book, the proceedings of Falk Symposium No. 123, VI International Symposium on Inflammatory Bowel Diseases, held in Istanbul, Turkey, on September 3-5, 2001, focuses on the issues and controversies pertinent to IBD in the 21st century. The achievements in medical, surgical, and in the basic sciences in the last twenty years since the first Jerusalem IBD Symposium are summarized in detail. Controversies with respect to the medical treatment of inflammatory bowel diseases are discussed. One section deals with surgical issues such as laparoscopic surgery in inflammatory bowel diseases, ileo-anal pouches and the surgical treatment of Crohn's disease. The last section is devoted to the biological treatment of IBD and to the needs both in medical science and in the clinic.
Ulcerative colitis and Crohn's disease remain a great therapeutic challenge to the medical community. In recent years knowledge about the pathogenesis of these diseases has progressed rapidly but the cause of the diseases remains completely unknown. It has become clear that dysregulation of the mucosal immune system is the basis for the chronic evolution of the diseases in a genetically susceptible population. Exciting new therapeutic approaches have been attempted in the last couple of years and cytokine and anti-cytokine treatments in particular seem very promising, especially in intractable disease. The format of the Falk Symposium 106 on `Advances in Inflammatory Bowel Diseases', held in Brussels, Belgium, June 18-20, 1998, was somewhat innovative as each session attempted to link the new insights into pathogenetic mechanisms with new therapeutic approaches, resulting in optimal information transfer. The classic therapeutic schemes were updated with a special focus on step-wise build-up of therapy.
The amount of information on the pathogenesis of inflammatory bowel disease is growing rapidly. This is reflected by a continuous increase in the number of papers presented at international GI meetings. To make things more difficult for practicing physicians, there is also a large number of new clinical trials being published which require periodical critical reviews and recommendations. Faced with these issues, the scientific commitee of the Falk Symposium No. 140 decided to take a different approach and to apply a novel format that is reflected in the title of the Symposium: "Translation from basic research to clinical practice". This book contains the proceedings of that Symposium, held in Dubrovnik, Croatia, on May 7–8, 2004. The sections are designed so that they start with the information from basic sciences on different aspects of these complex diseases and further lead to their clinical implications. Special attention is paid to the mechanisms of actions of established drugs. The last two sections are clinically oriented and focus on the most difficult aspects of both Crohn's disease and ulcerative colitis. This format provides state-of-the-art chapters by leading experts in the field and at the same time up-to-date information on the clinical application of the new knowledge.
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), both increasing in incidence, have become a major topic of basic and clinical research as well as clinical practice in hepatology. Experts in the field update the current concepts on the carcinogenesis of HCC and CC such as genetic alterations in the pathways of cell cylce and apoptosis regulation, the hypothesis of dedifferentiation of hepatocytes to the malignant phenotype vs that of activation of hepatic progenitor cells incapable of maturation (maturation arrest hypothesis). In spite of an increasing number of genetic alterations described in human HCC as well as cell regulatory pathways tested in experimental HCC models, the key hits causing progression of the cell cycle in imbalance with apoptosis, tissue invasive growth and metastatic potential of cell clones still remain elusive. Very powerful genomic and proteomic techniques are promising insights into the carcinogenesis of liver malignancies that will allow more efficient therapeutic strategies. The current concepts on risk profiling, surveillance of risk groups and therapeutic strategies are evidence-based for HCC and less detailed for CC. Surveillance of risk groups improves detection of liver tumours in curable stages. Best strategies for curative treatment of HCC use neoadjuvant antitumour therapies before liver transplantation and a role is emerging for living donor-related liver transplantation. New palliative therapies for HCC are in the experimental stage with biological response modifiers, including angiogenesis inhibitors, and entering phase II clinical trials with the alpha-fetoprotein derived vaccines.